News of a new weight loss drug called Adipotide surfaced early last year, but there haven’t been many updates since July regarding the status of the drug’s development. As reports suggest, Adipotide is still in trial phase being tested in clinical studies on humans. If approved, it would join Qsymia, Belviq and several others in the ‘miracle’ weight loss prescription drug line-up.
Adipotide was created by Dr. Wadih Arap and Renata Pasqualini as a form of cancer treatment as it was designed to starve cancer cells of blood supply prohibit them from growing. However, the effects of Adipotide have actually shown it starves fat cells of blood, which forces them to die and be reabsorbed into the body.
Though successful initial trials have been completed on rats and monkeys, some negative side effects have been noted, including dehydration and small kidney lesions that left untreated could lead to kidney failure.
Diets in Review resident pharmacist Dr. Sarah G Khan reports that Adipotide will be marketed as an injection into the subcutaneous layer of the skin, administered directly into the fat. While this may seem more effective, she believes this could be a potential downside as this method is not as user friendly. (more…)
With the help of a new medication, fat may be getting its eviction notice from your body very soon. A new experimental drug called Adipotide cuts off blood supply to fat cells causing them to die. A very innovative idea compared to the current weight loss drug options.
Current weight loss drugs that are available control the appetite, increase the body’s temperature, and decrease the amount of fat absorbed from the diet. Adipotide is targeted to a specific protein called prohibitin that is highly populated on blood vessels that lead to fat cells. Without blood supporting the growth of these fat cells they cannot sustain themselves. The dead cells are reabsorbed into the body.
Currently Adipotide is in the beginning stages of testing. The concept came from a scientist developing a cancer drug trying to cut off the blood supply to cancerous cells so they would not continue to grow. Most clinical trials begin with rats and if considered safe usually move on to healthy male subjects. Adipotide was initially tested in rats and the results showed a 30 percent decrease in body weight. The next step was to test in monkeys, being that they are the species that most closely resembles humans. Adipotide was administered to the monkeys by injection and the dosage was based on their weight. It was given to them for 28 days and then they had a 28-day rest period. What they discovered was that obese monkeys lost about 11 percent of their body weight. (more…)